| pubmed-article:15110879 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0441767 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C1513784 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:15110879 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
| pubmed-article:15110879 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15110879 | pubmed:dateCreated | 2004-4-27 | lld:pubmed |
| pubmed-article:15110879 | pubmed:abstractText | A prospective randomised phase III study in patients < or =65 years old with previously untreated multiple myeloma (MM), intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue was compared with intensive chemotherapy alone. This economic evaluation was based on detailed data from patient charts and hospital information systems. In the intention-to-treat analysis, mean total treatment and follow-up costs of the myeloablative treatment arm were 81,643 euros compared to 68,802 euros for the chemotherapy arm (P=0.09). Costs per quality-adjusted life year were 51,357 euros versus 37,328 euros. In the clinical study, no significant differences were found in overall survival after a median follow-up of 33 months from randomisation. Intensive chemotherapy is regarded as standard therapy for younger patients with previously untreated MM. Cost-effectiveness of myeloma therapy after 3 years of follow up seems not to be favoured by myeloablative treatment with autologous stem-cell rescue. | lld:pubmed |
| pubmed-article:15110879 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15110879 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15110879 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15110879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15110879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15110879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15110879 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15110879 | pubmed:month | May | lld:pubmed |
| pubmed-article:15110879 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:SonneveldPP | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:LokhorstH MHM | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:Uyl-de... | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:SegerenC MCM | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:BuijtII | lld:pubmed |
| pubmed-article:15110879 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:15110879 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15110879 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:15110879 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15110879 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15110879 | pubmed:pagination | 1159-69 | lld:pubmed |
| pubmed-article:15110879 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:meshHeading | pubmed-meshheading:15110879... | lld:pubmed |
| pubmed-article:15110879 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15110879 | pubmed:articleTitle | A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. | lld:pubmed |
| pubmed-article:15110879 | pubmed:affiliation | Institute for Medical Technology Assessment, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands. vanagthoven@bmg.eur.nl | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15110879 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15110879 | lld:pubmed |
